Chemokines in tissue fibrosis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 7, 2013, Pages 1041-1048

  Sahin, Hacer ^a   Wasmuth, Hermann E ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Chemokine; Kidney; Liver; Lung; Skin; Tissue fibrosis

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CHEMOKINE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 4; RANTES; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; BASOPHIL; CELL ACTIVATION; CELL DIFFERENTIATION; CELL PROLIFERATION; DENDRITIC CELL; DISEASE COURSE; ENDOTHELIUM CELL; EOSINOPHIL; EPITHELIZATION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROGENESIS; FIBROSIS; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; KIDNEY FIBROSIS; LIVER FIBROSIS; LUNG FIBROSIS; MONOCYTE; MYOFIBROBLAST; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SCAR FORMATION; SCLERODERMA; SKIN FIBROSIS; TH1 CELL; TH2 CELL; THROMBOCYTE; WOUND HEALING; ANIMAL; LIVER CIRRHOSIS; METABOLISM;

ANIMALIA;

ANIMALS; CHEMOKINES; FIBROBLASTS; FIBROSIS; HUMANS; LIVER CIRRHOSIS;

EID: 84877015934     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.11.004     Document Type: Review

References (120)

1. Kisseleva T., Brenner D.A. Mechanisms of fibrogenesis. Exp. Biol. Med. (Maywood) 2008, 233:109-122.
2. Mutsaers S.E., Bishop J.E., McGrouther G., Laurent G.J. Mechanisms of tissue repair: from wound healing to fibrosis. Int. J. Biochem. Cell Biol. 1997, 29:5-17.
3. Razzaque M.S., Taguchi T. Pulmonary fibrosis: cellular and molecular events. Pathol. Int. 2003, 53:133-145.
4. Parola M., Robino G. Oxidative stress-related molecules and liver fibrosis. J. Hepatol. 2001, 35:297-306.
5. Marra F., Aleffi S., Galastri S., Provenzano A. Mononuclear cells in liver fibrosis. Semin. Immunopathol. 2009, 31:345-358.
6. Fernandez M., Semela D., Bruix J., Colle I., Pinzani M., Bosch J. Angiogenesis in liver disease. J. Hepatol. 2009, 50:604-620.
7. Strieter R.M., Burdick M.D., Gomperts B.N., Belperio J.A., Keane M.P. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev. 2005, 16:593-609.
8. Sahin H., Trautwein C., Wasmuth H.E. Functional role of chemokines in liver disease models. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:682-690.
9. Serhan C.N., Chiang N., Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 2008, 8:349-361.
10. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11:723-737.
11. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front. Biosci. 2008, 13:453-461.
12. Laskin D.L., Sunil V.R., Gardner C.R., Laskin J.D. Macrophages and tissue injury: agents of defense or destruction?. Annu. Rev. Pharmacol. Toxicol. 2011, 51:267-288.
13. Higashi-Kuwata N., Makino T., Inoue Y., Takeya M., Ihn H. Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma. Exp. Dermatol. 2009, 18:727-729.
14. Prokop S., Heppner F.L., Goebel H.H., Stenzel W. M2 polarized macrophages and giant cells contribute to myofibrosis in neuromuscular sarcoidosis. Am. J. Pathol. 2011, 178:1279-1286.
15. Romagnani S. Regulation of the T cell response. Clin. Exp. Allergy 2006, 36:1357-1366.
16. Wynn T.A. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat. Rev. Immunol. 2004, 4:583-594.
17. Thabut D., Shah V. Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?. J. Hepatol. 2010, 53:976-980.
18. Kalluri R., Sukhatme V.P. Fibrosis and angiogenesis. Curr. Opin. Nephrol. Hypertens. 2000, 9:413-418.
19. Corpechot C., Barbu V., Wendum D., Kinnman N., Rey C., Poupon R., Housset C., Rosmorduc O. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002, 35:1010-1021.
20. Fine L.G., Norman J.T. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int. 2008, 74:867-872.
21. Rosmorduc O., Housset C. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin. Liver Dis. 2010, 30:258-270.
22. Bonecchi R., Galliera E., Borroni E.M., Corsi M.M., Locati M., Mantovani A. Chemokines and chemokine receptors: an overview. Front. Biosci. 2009, 14:540-551.
23. Colvin R.A., Campanella G.S., Sun J., Luster A.D. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J. Biol. Chem. 2004, 279:30219-30227.
24. Liu L., Callahan M.K., Huang D., Ransohoff R.M. Chemokine receptor CXCR3: an unexpected enigma. Curr. Top. Dev. Biol. 2005, 68:149-181.
25. Wasmuth H.E., Tacke F., Trautwein C. Chemokines in liver inflammation and fibrosis. Semin. Liver Dis. 2010, 30:215-225.
26. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669.
27. Medina J., Arroyo A.G., Sanchez-Madrid F., Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004, 39:1185-1195.
28. Karlmark K.R., Wasmuth H.E., Trautwein C., Tacke F. Chemokine-directed immune cell infiltration in acute and chronic liver disease. Expert Rev. Gastroenterol. Hepatol. 2008, 2:233-242.
29. Oo Y.H., Adams D.H. The role of chemokines in the recruitment of lymphocytes to the liver. J. Autoimmun. 2010, 34:45-54.
30. Holt A.P., Haughton E.L., Lalor P.F., Filer A., Buckley C.D., Adams D.H. Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver. Gastroenterology 2009, 136:705-714.
31. Hong F., Tuyama A., Lee T.F., Loke J., Agarwal R., Cheng X., Garg A., Fiel M.I., Schwartz M., Walewski J., Branch A., Schecter A.D., Bansal M.B. Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-1alpha-mediated stellate cell activation. Hepatology 2009, 49:2055-2067.
32. Keeley E.C., Mehrad B., Strieter R.M. Chemokines as mediators of neovascularization. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1928-1936.
33. Seki E., De Minicis S., Gwak G.Y., Kluwe J., Inokuchi S., Bursill C.A., Llovet J.M., Brenner D.A., Schwabe R.F. CCR1 and CCR5 promote hepatic fibrosis in mice. J. Clin. Invest. 2009, 119:1858-1870.
34. Goulding C., McManus R., Murphy A., MacDonald G., Barrett S., Crowe J., Hegarty J., McKiernan S., Kelleher D. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 2005, 54:1157-1161.
35. Berres M.L., Koenen R.R., Rueland A., Zaldivar M.M., Heinrichs D., Sahin H., Schmitz P., Streetz K.L., Berg T., Gassler N., Weiskirchen R., Proudfoot A., Weber C., Trautwein C., Wasmuth H.E. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J. Clin. Invest. 2010, 120:4129-4140.
36. Nellen A., Heinrichs D., Berres M.L., Sahin H., Schmitz P., Proudfoot A.E., Trautwein C., Wasmuth H.E. Interference with oligomerization and glycosaminoglycan binding of the chemokine CCL5 improves experimental liver injury. PLoS One 2012, 7:e36614.
37. Caligiuri A., Bertolani C., Guerra C.T., Aleffi S., Galastri S., Trappoliere M., Vizzutti F., Gelmini S., Laffi G., Pinzani M., Marra F. Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. Hepatology 2008, 47:668-676.
38. Marra F., DeFranco R., Grappone C., Milani S., Pastacaldi S., Pinzani M., Romanelli R.G., Laffi G., Gentilini P. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am. J. Pathol. 1998, 152:423-430.
39. Loetscher P., Seitz M., Baggiolini M., Moser B. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J. Exp. Med. 1996, 184:569-577.
40. Sozzani S., Luini W., Borsatti A., Polentarutti N., Zhou D., Piemonti L., D'Amico G., Power C.A., Wells T.N., Gobbi M., Allavena P., Mantovani A. Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J. Immunol. 1997, 159:1993-2000.
41. Geissmann F., Jung S., Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82.
42. Seki E., de Minicis S., Inokuchi S., Taura K., Miyai K., van Rooijen N., Schwabe R.F., Brenner D.A. CCR2 promotes hepatic fibrosis in mice. Hepatology 2009, 50:185-197.
43. Karlmark K.R., Weiskirchen R., Zimmermann H.W., Gassler N., Ginhoux F., Weber C., Merad M., Luedde T., Trautwein C., Tacke F. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 2009, 50:261-274.
44. Heymann F., Hammerich L., Storch D., Bartneck M., Huss S., Russeler V., Gassler N., Lira S.A., Luedde T., Trautwein C., Tacke F. Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor C-C motif chemokine receptor 8 in mice. Hepatology 2012, 55:898-909.
45. Santodomingo-Garzon T., Han J., Le T., Yang Y., Swain M.G. Natural killer T cells regulate the homing of chemokine CXC receptor 3-positive regulatory T cells to the liver in mice. Hepatology 2009, 49:1267-1276.
46. Lasagni L., Francalanci M., Annunziato F., Lazzeri E., Giannini S., Cosmi L., Sagrinati C., Mazzinghi B., Orlando C., Maggi E., Marra F., Romagnani S., Serio M., Romagnani P. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J. Exp. Med. 2003, 197:1537-1549.
47. Pesce J., Kaviratne M., Ramalingam T.R., Thompson R.W., Urban J.F., Cheever A.W., Young D.A., Collins M., Grusby M.J., Wynn T.A. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J. Clin. Invest. 2006, 116:2044-2055.
48. Shi Z., Wakil A.E., Rockey D.C. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:10663-10668.
49. Syrbe U., Siveke J., Hamann A. Th1/Th2 subsets: distinct differences in homing and chemokine receptor expression?. Springer Semin. Immunopathol. 1999, 21:263-285.
50. Wasmuth H.E., Lammert F., Zaldivar M.M., Weiskirchen R., Hellerbrand C., Scholten D., Berres M.L., Zimmermann H., Streetz K.L., Tacke F., Hillebrandt S., Schmitz P., Keppeler H., Berg T., Dahl E., Gassler N., Friedman S.L., Trautwein C. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 2009, 137:309-319. (319 e301-303).
51. Sahin H., Borkham-Kamphorst E., Kuppe C., Zaldivar M.M., Grouls C., Al-samman M., Nellen A., Schmitz P., Heinrichs D., Berres M.L., Doleschel D., Scholten D., Weiskirchen R., Moeller M.J., Kiessling F., Trautwein C., Wasmuth H.E. Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice. Hepatology 2012, 55:1610-1619.
52. Hintermann E., Bayer M., Pfeilschifter J.M., Luster A.D., Christen U. CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation. J. Autoimmun. 2010, 35:424-435.
53. Zeremski M., Petrovic L.M., Chiriboga L., Brown Q.B., Yee H.T., Kinkhabwala M., Jacobson I.M., Dimova R., Markatou M., Talal A.H. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008, 48:1440-1450.
54. Berres M.L., Trautwein C., Schmeding M., Eurich D., Tacke F., Bahra M., Neuhaus P., Neumann U.P., Wasmuth H.E. Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection. Hepatology 2011, 53:596-603.
55. Casrouge A., Decalf J., Ahloulay M., Lababidi C., Mansour H., Vallet-Pichard A., Mallet V., Mottez E., Mapes J., Fontanet A., Pol S., Albert M.L. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J. Clin. Invest. 2011, 121:308-317.
56. Zaldivar M.M., Pauels K., von Hundelshausen P., Berres M.L., Schmitz P., Bornemann J., Kowalska M.A., Gassler N., Streetz K.L., Weiskirchen R., Trautwein C., Weber C., Wasmuth H.E. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 2010, 51:1345-1353.
57. von Hundelshausen P., Koenen R.R., Sack M., Mause S.F., Adriaens W., Proudfoot A.E., Hackeng T.M., Weber C. Heterophilic interactions of platelet factor 4 and RANTES promote monocyte arrest on endothelium. Blood 2005, 105:924-930.
58. Karlmark K.R., Zimmermann H.W., Roderburg C., Gassler N., Wasmuth H.E., Luedde T., Trautwein C., Tacke F. The fractalkine receptor CX(3)CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology 2010, 52:1769-1782.
59. Chua F., Gauldie J., Laurent G.J. Pulmonary fibrosis: searching for model answers. Am. J. Respir. Cell Mol. Biol. 2005, 33:9-13.
60. Metz C.N. Fibrocytes: a unique cell population implicated in wound healing. Cell. Mol. Life Sci. 2003, 60:1342-1350.
61. Hogaboam C.M., Bone-Larson C.L., Lipinski S., Lukacs N.W., Chensue S.W., Strieter R.M., Kunkel S.L. Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1- and Th2-type pulmonary granuloma models. J. Immunol. 1999, 163:2193-2201.
62. Fehrenbach H. Alveolar epithelial type II cell: defender of the alveolus revisited. Respir. Res. 2001, 2:33-46.
63. Williams M.C. Alveolar type I cells: molecular phenotype and development. Annu. Rev. Physiol. 2003, 65:669-695.
64. Inoshima I., Kuwano K., Hamada N., Hagimoto N., Yoshimi M., Maeyama T., Takeshita A., Kitamoto S., Egashira K., Hara N. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286:L1038-L1044.
65. Gharaee-Kermani M., Phan S.H. Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis. Curr. Pharm. Des. 2005, 11:3943-3971.
66. Frade J.M., Mellado M., del Real G., Gutierrez-Ramos J.C., Lind P., Martinez A.C. Characterization of the CCR2 chemokine receptor: functional CCR2 receptor expression in B cells. J. Immunol. 1997, 159:5576-5584.
67. Moore B.B., Paine R., Christensen P.J., Moore T.A., Sitterding S., Ngan R., Wilke C.A., Kuziel W.A., Toews G.B. Protection from pulmonary fibrosis in the absence of CCR2 signaling. J. Immunol. 2001, 167:4368-4377.
68. Okuma T., Terasaki Y., Kaikita K., Kobayashi H., Kuziel W.A., Kawasuji M., Takeya M. C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases. J. Pathol. 2004, 204:594-604.
69. Capelli A., Di Stefano A., Gnemmi I., Donner C.F. CCR5 expression and CC chemokine levels in idiopathic pulmonary fibrosis. Eur. Respir. J. 2005, 25:701-707.
70. Blanpain C., Migeotte I., Lee B., Vakili J., Doranz B.J., Govaerts C., Vassart G., Doms R.W., Parmentier M. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 1999, 94:1899-1905.
71. Ishida Y., Kimura A., Kondo T., Hayashi T., Ueno M., Takakura N., Matsushima K., Mukaida N. Essential roles of the CC chemokine ligand 3-CC chemokine receptor 5 axis in bleomycin-induced pulmonary fibrosis through regulation of macrophage and fibrocyte infiltration. Am. J. Pathol. 2007, 170:843-854.
72. Tokuda A., Itakura M., Onai N., Kimura H., Kuriyama T., Matsushima K. Pivotal role of CCR1-positive leukocytes in bleomycin-induced lung fibrosis in mice. J. Immunol. 2000, 164:2745-2751.
73. Huaux F., Gharaee-Kermani M., Liu T., Morel V., McGarry B., Ullenbruch M., Kunkel S.L., Wang J., Xing Z., Phan S.H. Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis. Am. J. Pathol. 2005, 167:1485-1496.
74. Pope S.M., Zimmermann N., Stringer K.F., Karow M.L., Rothenberg M.E. The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia. J. Immunol. 2005, 175:5341-5350.
75. Strieter R.M., Gomperts B.N., Keane M.P. The role of CXC chemokines in pulmonary fibrosis. J. Clin. Invest. 2007, 117:549-556.
76. Izbicki G., Or R., Christensen T.G., Segel M.J., Fine A., Goldstein R.H., Breuer R. Bleomycin-induced lung fibrosis in IL-4-overexpressing and knockout mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002, 283:L1110-L1116.
77. Jiang D., Liang J., Hodge J., Lu B., Zhu Z., Yu S., Fan J., Gao Y., Yin Z., Homer R., Gerard C., Noble P.W. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J. Clin. Invest. 2004, 114:291-299.
78. Nakaya I., Wada T., Furuichi K., Sakai N., Kitagawa K., Yokoyama H., Ishida Y., Kondo T., Sugaya T., Kawachi H., Shimizu F., Narumi S., Haino M., Gerard C., Matsushima K., Kaneko S. Blockade of IP-10/CXCR3 promotes progressive renal fibrosis. Nephron Exp. Nephrol. 2007, 107:e12-e21.
79. Keane M.P., Arenberg D.A., Lynch J.P., Whyte R.I., Iannettoni M.D., Burdick M.D., Wilke C.A., Morris S.B., Glass M.C., DiGiovine B., Kunkel S.L., Strieter R.M. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J. Immunol. 1997, 159:1437-1443.
80. Keane M.P., Belperio J.A., Burdick M.D., Lynch J.P., Fishbein M.C., Strieter R.M. ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2001, 164:2239-2242.
81. Keane M.P., Belperio J.A., Moore T.A., Moore B.B., Arenberg D.A., Smith R.E., Burdick M.D., Kunkel S.L., Strieter R.M. Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J. Immunol. 1999, 162:5511-5518.
82. Hanumegowda C., Farkas L., Kolb M. Angiogenesis in pulmonary fibrosis: too much or not enough?. Chest 2012, 142:200-207.
83. Burdick M.D., Murray L.A., Keane M.P., Xue Y.Y., Zisman D.A., Belperio J.A., Strieter R.M. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am. J. Respir. Crit. Care Med. 2005, 171:261-268.
84. Tager A.M., Kradin R.L., LaCamera P., Bercury S.D., Campanella G.S., Leary C.P., Polosukhin V., Zhao L.H., Sakamoto H., Blackwell T.S., Luster A.D. Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. Am. J. Respir. Cell Mol. Biol. 2004, 31:395-404.
85. Keane M.P., Belperio J.A., Arenberg D.A., Burdick M.D., Xu Z.J., Xue Y.Y., Strieter R.M. IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J. Immunol. 1999, 163:5686-5692.
86. Keane M.P., Belperio J.A., Burdick M.D., Strieter R.M. IL-12 attenuates bleomycin-induced pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 281:L92-L97.
87. Vielhauer V., Anders H.J., Mack M., Cihak J., Strutz F., Stangassinger M., Luckow B., Grone H.J., Schlondorff D. Obstructive nephropathy in the mouse: progressive fibrosis correlates with tubulointerstitial chemokine expression and accumulation of CC chemokine receptor 2- and 5-positive leukocytes. J. Am. Soc. Nephrol. 2001, 12:1173-1187.
88. Banba N., Nakamura T., Matsumura M., Kuroda H., Hattori Y., Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int. 2000, 58:684-690.
89. Wada T., Furuichi K., Sakai N., Iwata Y., Yoshimoto K., Shimizu M., Takeda S.I., Takasawa K., Yoshimura M., Kida H., Kobayashi K.I., Mukaida N., Naito T., Matsushima K., Yokoyama H. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int. 2000, 58:1492-1499.
90. Lloyd C.M., Minto A.W., Dorf M.E., Proudfoot A., Wells T.N., Salant D.J., Gutierrez-Ramos J.C. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J. Exp. Med. 1997, 185:1371-1380.
91. Tesch G.H., Schwarting A., Kinoshita K., Lan H.Y., Rollins B.J., Kelley V.R. Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. J. Clin. Invest. 1999, 103:73-80.
92. Anders H.J., Vielhauer V., Frink M., Linde Y., Cohen C.D., Blattner S.M., Kretzler M., Strutz F., Mack M., Grone H.J., Onuffer J., Horuk R., Nelson P.J., Schlondorff D. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J. Clin. Invest. 2002, 109:251-259.
93. Perez de Lema G., Maier H., Nieto E., Vielhauer V., Luckow B., Mampaso F., Schlondorff D. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J. Am. Soc. Nephrol. 2001, 12:1369-1382.
94. Tesch G.H., Maifert S., Schwarting A., Rollins B.J., Kelley V.R. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J. Exp. Med. 1999, 190:1813-1824.
95. Belperio J.A., Keane M.P., Burdick M.D., Lynch J.P., Xue Y.Y., Berlin A., Ross D.J., Kunkel S.L., Charo I.F., Strieter R.M. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J. Clin. Invest. 2001, 108:547-556.
96. Lee S.K., Park J.Y., Chung S.J., Yang W.S., Kim S.B., Park S.K., Park J.S. Chemokines, osteopontin, ICAM-1 gene expression in cultured rat mesangial cells. J. Korean Med. Sci. 1998, 13:165-170.
97. Segerer S., Mac K.M., Regele H., Kerjaschki D., Schlondorff D. Expression of the C-C chemokine receptor 5 in human kidney diseases. Kidney Int. 1999, 56:52-64.
98. Turner J.E., Paust H.J., Bennstein S.B., Bramke P., Krebs C., Steinmetz O.M., Velden J., Haag F., Stahl R.A., Panzer U. Protective role for CCR5 in murine lupus nephritis. Am. J. Physiol. Renal Physiol. 2012, 302:F1503-F1515.
99. Song E., Zou H., Yao Y., Proudfoot A., Antus B., Liu S., Jens L., Heemann U. Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney Int. 2002, 61:676-685.
100. Fischereder M., Luckow B., Hocher B., Wuthrich R.P., Rothenpieler U., Schneeberger H., Panzer U., Stahl R.A., Hauser I.A., Budde K., Neumayer H., Kramer B.K., Land W., Schlondorff D. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001, 357:1758-1761.
101. Bedke J., Kiss E., Schaefer L., Behnes C.L., Bonrouhi M., Gretz N., Horuk R., Diedrichs-Moehring M., Wildner G., Nelson P.J., Grone H.J. Beneficial effects of CCR1 blockade on the progression of chronic renal allograft damage. Am. J. Transplant. 2007, 7:527-537.
102. Hasegawa M., Sato S. The roles of chemokines in leukocyte recruitment and fibrosis in systemic sclerosis. Front. Biosci. 2008, 13:3637-3647.
103. Hasegawa M., Sato S., Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin. Exp. Immunol. 1999, 117:159-165.
104. Denton C.P., Shi-Wen X., Sutton A., Abraham D.J., Black C.M., Pearson J.D. Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin. Exp. Immunol. 1998, 114:293-300.
105. Zhang Y., McCormick L.L., Desai S.R., Wu C., Gilliam A.C. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J. Immunol. 2002, 168:3088-3098.
106. Ferreira A.M., Takagawa S., Fresco R., Zhu X., Varga J., DiPietro L.A. Diminished induction of skin fibrosis in mice with MCP-1 deficiency. J. Invest. Dermatol. 2006, 126:1900-1908.
107. Yamamoto T., Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J. Invest. Dermatol. 2003, 121:510-516.
108. Kimura M., Kawahito Y., Hamaguchi M., Nakamura T., Okamoto M., Matsumoto Y., Endo H., Yamamoto A., Ishino H., Wada M., Omoto A., Tsubouchi Y., Kohno M., Yoshikawa T. SKL-2841, a dual antagonist of MCP-1 and MIP-1 beta, prevents bleomycin-induced skin sclerosis in mice. Biomed. Pharmacother. 2007, 61:222-228.
109. Bolster M.B., Ludwicka A., Sutherland S.E., Strange C., Silver R.M. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum. 1997, 40:743-751.
110. Distler O., Rinkes B., Hohenleutner U., Scholmerich J., Landthaler M., Lang B., Gay S., Muller-Ladner U. Expression of RANTES in biopsies of skin and upper gastrointestinal tract from patients with systemic sclerosis. Rheumatol. Int. 1999, 19:39-46.
111. Anderegg U., Saalbach A., Haustein U.F. Chemokine release from activated human dermal microvascular endothelial cells-implications for the pathophysiology of scleroderma?. Arch. Dermatol. Res. 2000, 292:341-347.
112. Yanaba K., Komura K., Kodera M., Matsushita T., Hasegawa M., Takehara K., Sato S. Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Ann. Rheum. Dis. 2006, 65:124-126.
113. Ong V.H., Evans L.A., Shiwen X., Fisher I.B., Rajkumar V., Abraham D.J., Black C.M., Denton C.P. Monocyte chemoattractant protein 3 as a mediator of fibrosis: overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum. 2003, 48:1979-1991.
114. Fujii H., Shimada Y., Hasegawa M., Takehara K., Sato S. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis. J. Dermatol. Sci. 2004, 35:43-51.
115. Hayakawa I., Hasegawa M., Matsushita T., Yanaba K., Kodera M., Komura K., Takehara K., Sato S. Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis. Rheumatology (Oxford) 2005, 44:873-878.
116. Furuse S., Fujii H., Kaburagi Y., Fujimoto M., Hasegawa M., Takehara K., Sato S. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. J. Rheumatol. 2003, 30:1524-1528.
117. Lee E.B., Zhao J., Kim J.Y., Xiong M., Song Y.W. Evidence of potential interaction of chemokine genes in susceptibility to systemic sclerosis. Arthritis Rheum. 2007, 56:2443-2448.
118. Rabquer B.J., Tsou P.S., Hou Y., Thirunavukkarasu E., Haines G.K., Impens A.J., Phillips K., Kahaleh B., Seibold J.R., Koch A.E. Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Res. Ther. 2011, 13:R18.
119. Ajuebor M.N., Wondimu Z., Hogaboam C.M., Le T., Proudfoot A.E., Swain M.G. CCR5 deficiency drives enhanced natural killer cell trafficking to and activation within the liver in murine T cell-mediated hepatitis. Am. J. Pathol. 2007, 170:1975-1988.
120. Koenen R.R., von Hundelshausen P., Nesmelova I.V., Zernecke A., Liehn E.A., Sarabi A., Kramp B.K., Piccinini A.M., Paludan S.R., Kowalska M.A., Kungl A.J., Hackeng T.M., Mayo K.H., Weber C. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat. Med. 2009, 15:97-103.